3 not yet recruiting, 3 recruiting. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 3, Recruiting 3 |
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Daraxonrasib: new trials by email Literature Review of Daraxonrasib trials Research Report on Daraxonrasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | National Health Research Institutes, Taiwan | 55 | 2027-01-01 | 2026-11-02 |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Navlimetostat, Daraxonrasib, Temozolomide - Solid Tumors | Phase 2 | Recruiting | Bristol-Myers Squibb | 254 | 2026-07-27 | 2026-11-02 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Elironrasib, Daraxonrasib - Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 534 | 2023-11-14 | 2026-09-22 |
Biliary Tract Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Appendiceal Neoplasms (1) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Pancreatic Ductal (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colonic Neoplasms (1)
Revolution Medicines, Inc. (2) · Bristol-Myers Squibb (1) · Children's Oncology Group (1) · National Health Research Institutes, Taiwan (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (4) · France (2) · Germany (2) · Italy (2) · Spain (2) · Belgium (1) · Canada (1) · China (1) · Hong Kong (1) · Ireland (1) · Japan (1) · Netherlands (1) · Norway (1) · Puerto Rico (1) · South Korea (1)
Amit J Sabnis (1) · Nilo Azad, MD (1) · Revolution Medicines, Inc. (1)
2025 (1), UM1CA228823 (1)